Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]
Synonyms
2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid
Gemfibrozil
Gemfibrozilum
2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure
Gemfibrozilo
2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansäure
Brand Names
Penta-gemfibrozil
Lopid
Teva-gemfibrozil
Scheinpharm Gemfibrozil
Riva-gemfibrozil
Dom-gemfibrozil
Nu-gemfibrozil Cap 300mg
Gemfibrozil Cap 300mg
Gemfibrozil Tab 600mg
Gemfibrozil-300 - Cap
Mylan-gemfibrozil
Gemfibrozil
Apo-gemfibrozil
Lopid Cap 300mg
PMS-gemfibrozil
Nu-gemfibrozil Tab 600mg
Apo-gemfibrozil Cap 300mg USP
Gemfibrozil-600 - Tab 600mg
Lopid 600mg
PHL-gemfibrozil
Indication
Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions.[L8525] Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.[L8525]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
